Mira M. Milas, M.D., F.A.C.S.

Head Shot of Mira Milas
Special Interest:
Thyroid Cancer
Accepting Patients:


Dr. Milas is an endocrine surgeon who is devoted to compassionate and expert care of patients with thyroid and parathyroid disorders. Her background includes specialized training in general surgery, surgical oncology and endocrine surgery from Emory University School of Medicine and The University of Texas M. D. Anderson Cancer Center. She was the founding director of the Thyroid Center at Cleveland Clinic, and is involved in numerous national and international activities in the field of thyroid and parathyroid disease.At the OHSU Knight Cancer Institute, Dr. Milas will join the multidisciplinary oncology team, providing a full range of diagnosis and treatment services to patients with endocrine tumors, especially thyroid cancer. She serves as Director of Endocrine Surgery and member of the multidisciplinary Thyroid and Parathyroid Center. Her expertise also includes benign thyroid and parathyroid tumors, such as nodular thyroid disease and goiters, and hyperparathyroidism that can lead to kidney stones and significant osteoporosis. With long-standing commitments to education and innovation, Dr. Milas’ research interests focus on molecular markers for thyroid cancer diagnosis, circulating cancer cells, hereditary thyroid cancer syndromes and novel phenotypes of parathyroid disease.

Professional Education

  • Degree:
    M.D., The University of Texas, Houston, Texas
  • Residency:
    Emory University Affiliated Hospitals, Atlanta, Ga.
  • Fellowship:
    Endocrine Surgery, Emory University School of Medicine, Atlanta, Ga. Surgical Oncology Research, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
  • Certification:
    American Board of Surgery

OHSU Knight Cancer Institute

Visit our site

Provider Referral Line

503 494-2544

I see patients at:

Physicians Pavilion

Insurance Information

OHSU accepts most insurance plans

Insurance Information

Clinical Trials

The following clinical trials are currently accepting new participants:

Oregon Index of Endocrine Neoplasias (ORION)

Search all studies